CZ122697A3 - Preparations and methods of treating disseminated sclerosis - Google Patents

Preparations and methods of treating disseminated sclerosis Download PDF

Info

Publication number
CZ122697A3
CZ122697A3 CZ971226A CZ122697A CZ122697A3 CZ 122697 A3 CZ122697 A3 CZ 122697A3 CZ 971226 A CZ971226 A CZ 971226A CZ 122697 A CZ122697 A CZ 122697A CZ 122697 A3 CZ122697 A3 CZ 122697A3
Authority
CZ
Czechia
Prior art keywords
mbp
peptide
group
peptides
multiple sclerosis
Prior art date
Application number
CZ971226A
Other languages
Czech (cs)
English (en)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of CZ122697A3 publication Critical patent/CZ122697A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ971226A 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis CZ122697A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
CZ122697A3 true CZ122697A3 (en) 1997-09-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ971226A CZ122697A3 (en) 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (xx)
JP (1) JPH10504039A (xx)
AU (1) AU4278296A (xx)
BR (1) BR9509438A (xx)
CA (1) CA2203629A1 (xx)
CZ (1) CZ122697A3 (xx)
FI (1) FI971750A (xx)
HU (1) HUT77047A (xx)
IL (1) IL115766A0 (xx)
IS (1) IS4466A (xx)
NO (1) NO971900L (xx)
PL (1) PL324091A1 (xx)
SI (1) SI9520118A (xx)
SK (1) SK51297A3 (xx)
WO (1) WO1996012737A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
DE69733343D1 (de) 1996-03-21 2005-06-30 Circassia Ltd Kryptische peptide und verfahren zu ihrer identifizierung
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (ja) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
JP4486365B2 (ja) 2002-03-27 2010-06-23 エーゲーラ セラピューティクス インコーポレイテッド アンチセンスｉａｐ核酸塩基オリゴマーおよびその使用
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
AU2010234743A1 (en) * 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CA2780961C (en) 2009-10-12 2018-10-02 Lifebio Laboratories Llc Composition for treatment of multiple sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
BR112013023978B1 (pt) 2011-03-21 2021-09-08 Atlantic Cancer Research Institute Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica
BR112016016153A2 (pt) 2014-01-13 2017-12-12 Berg Llc composições de enolase 1 (eno1) e usos das mesmas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
ES2144398T3 (es) * 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
EP0594607B1 (en) * 1990-03-02 1997-08-27 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral or enteral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
JP3712260B2 (ja) * 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
BR9306272A (pt) * 1992-04-09 1998-06-23 Autoimmune Inc Peptídeo e composiçao farmacêutica
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
EP0720622A1 (en) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
JPH09511990A (ja) * 1994-04-08 1997-12-02 ブリガム アンド ウィミンズ ホスピタル 経口寛容および／またはＴｈ２増強サイトカインを用いた自己免疫疾患の治療
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
EP0764273B1 (en) * 1994-06-09 1998-10-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2205532A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
WO1996012737A2 (en) 1996-05-02
IL115766A0 (en) 1996-01-19
JPH10504039A (ja) 1998-04-14
BR9509438A (pt) 1997-12-23
WO1996012737A3 (en) 1996-10-10
AU4278296A (en) 1996-05-15
NO971900L (no) 1997-06-25
PL324091A1 (en) 1998-05-11
SI9520118A (sl) 1998-08-31
HUT77047A (hu) 1998-03-02
FI971750A0 (fi) 1997-04-24
FI971750A (fi) 1997-06-24
IS4466A (is) 1997-04-17
CA2203629A1 (en) 1996-05-02
EP0787147A1 (en) 1997-08-06
NO971900D0 (no) 1997-04-24
SK51297A3 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
CZ122697A3 (en) Preparations and methods of treating disseminated sclerosis
EP1311542B1 (en) Tolerogenic peptides
US5858980A (en) Peptide fragments of myelin basic protein
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
WO1996012737A9 (en) Compositions and treatment for multiple sclerosis
EP1732595A2 (en) Identification of self and non-self antigens implicated in autoimmune diseases
Samson et al. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes.
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
TW496872B (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
JP2000512277A (ja) ペプチド誘導体
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
MXPA04007510A (es) Peptidos tolerogenicos de la proteina basica de mielina.
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
WO1997035879A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
JP2006525813A (ja) １型糖尿病において罹患性病原性ｔ細胞により標的とされる抗原ならびにこれの使用
EP2945966B1 (en) Peptide
KR100540417B1 (ko) 펩티드 면역 요법 치료제
CA3182369A1 (en) Combination treatment for fumarate-related diseases
Shen et al. Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse
US20230414732A1 (en) Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
EP2227486B1 (en) Peptide analogues and conjugates thereof
US6207389B1 (en) Methods of controlling T lymphocyte mediated immune responses
AU2019355062A1 (en) Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic